about
Clinical implications of aspirin resistanceThe GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend.Inhibition of platelet activation could decrease thrombotic events in hemodialysis PF4/H antibody-positive patients.Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.Pharmacometabolomics reveals that serotonin is implicated in aspirin response variabilityComparative efficacy of in vitro and in vivo metabolized aspirin in the DeBakey ventricular assist deviceMonitoring residual platelet activity among patients with acute coronary syndrome.New aspects on efficient anticoagulation and antiplatelet strategies in sheep.The use of quartz crystal microbalance with dissipation (QCM-D) for studying nanoparticle-induced platelet aggregation.Bleeding tendency in dual antiplatelet therapy with aspirin/clopidogrel: rescue of the template bleeding time in a single-center prospective study.Chinese Herbal Medicine for Aspirin Resistance: A Systematic Review and Meta-Analysis.Novel whole blood assay for phenotyping platelet reactivity in mice identifies ICAM-1 as a mediator of platelet-monocyte interactionDrug-Free Platelets Can Act as Seeds for Aggregate Formation During Antiplatelet Therapy.Prevalence and risk factors of clopidogrel non-response among Saudi patients undergoing coronary angiographyStatic platelet adhesion, flow cytometry and serum TXB2 levels for monitoring platelet inhibiting treatment with ASA and clopidogrel in coronary artery disease: a randomised cross-over studyInterindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the WoEffect of Oral Anti-platelet Regimens on Platelet Aggregation using Chronolog Light Transmittance Aggregometry in Coronary Heart Disease Patients: An Observational Study.A clinician's perspective of emerging P2Y(12)-directed pharmacotherapies, ex vivo measurement tools, and clinical outcomes.Antithrombotic therapy for the CardioWest temporary total artificial heart.Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy.Analysis of platelet function: role of microfluidics and nanodevices.A contemporary viewpoint on 'aspirin resistance'.Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.Advances in monitoring of aspirin therapy.Advances in the monitoring of anti-P2Y12 therapy.Percutaneous native kidney biopsy in patients receiving antiplatelet agents- is it necessary to stop them routinely?Comparative evaluation of antiplatelet effect of lycopene with aspirin and the effect of their combination on platelet aggregation: An in vitro study.Validation of Three Platelet Function Tests for Bleeding Risk Stratification During Dual Antiplatelet Therapy Following Coronary Interventions.Coadministration of ticagrelor and ritonavir: Toward prospective dose adjustment to maintain an optimal platelet inhibition using the PBPK approach.Effect of palm-based tocotrienols and tocopherol mixture supplementation on platelet aggregation in subjects with metabolic syndrome: a randomised controlled trial.The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrelPharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel?Validation of a procedure to assess ASA-response in patients with decreased, initial TRAP induced aggregation.Evaluation of antiplatelet effects of a modified protocol by platelet aggregation in patients undergoing "one-stop" hybrid coronary revascularization.VerifyNow and VASP phosphorylation assays give similar results for patients receiving clopidogrel, but they do not always correlate with platelet aggregation.Evaluation of aspirin response by Multiplate whole blood aggregometry and light transmission aggregometry.Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy.Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin.Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation.
P2860
Q28221576-07D521C0-463B-4A22-9641-7D2174EEBC5BQ33381441-2DF825D2-AFE8-44EB-88C9-6C81E6C2CA16Q33414182-16BE8B21-40EA-472F-8F50-19C600B09B59Q33863833-6EBC4709-4D0C-45BB-8A1E-256E293D4D7AQ33994559-9F008DC8-65DD-4FDF-BB1A-C81A47A95B0BQ34159316-4F3AF848-83FC-4B2B-B20C-27159C3B0EA1Q34459024-853788AA-F22C-44D3-A2FC-E545AAB5AA89Q35006714-EABBEE96-0725-4BB9-B419-C918A845A404Q35686931-ADF6AFD2-7AEB-4A96-A0FF-5EF0C597A835Q35707491-9D5DB662-DAE2-4AEA-AF35-1608436FEEE6Q36010925-220D1516-E175-4C43-91FF-263FFC121A1EQ36027470-EA73E56F-637D-469D-B6BA-983DA8E7ACEBQ36104404-B4A13014-38A4-46BA-83DA-AC6F1740A020Q36709544-626CB16E-F474-4A4D-B4C1-1BACCAB1FFA3Q37234897-45F46423-42D8-4A64-B86B-619A0833ABA4Q37378896-52D9F595-27D4-4D5D-9039-5493A7FF53ACQ37429557-BB4ABDB7-94DA-4A81-AF9F-78E8C34B7B67Q37550156-4D9CF8BD-F603-464D-A590-93FE0FF64A2CQ37733290-B89BD543-183A-490E-B02A-ED2BCA66B19BQ37841572-5BB3EBFD-2E91-4629-AF88-415196526346Q37949602-6BD922CB-D57B-4F8C-AF9C-F835F8EB1014Q37989558-EFE92423-5F43-41F2-8F3A-770E25994C70Q38012079-13772B5B-5F28-4D82-B66F-882DE7E6B4A2Q38032895-7FB93ABD-DE99-4464-A536-5C62820D5219Q38037121-4576AF6E-D13A-4CF5-8E62-73137B60D8ECQ38523257-AF84579A-35FC-4D5E-BF59-614102994890Q38776693-F762C72F-3479-420C-A263-B23D9AE5BA8CQ38847255-CBC80992-7F54-4B49-96C6-E3554FDE4CBFQ40717885-DF0BC63E-281D-41ED-9F9A-7D0EB209B3E2Q41049503-01385B03-6748-4C1A-B7F1-374E6D2748F4Q42159559-9E6A6714-CE8E-42C5-A7E4-AF45F6BD4351Q42164176-BBC77559-9837-44AE-B1B4-5A8ED12D70B6Q42972735-300A123B-7AE6-4846-BF34-43CBE4F2FA53Q43076122-FA283A6E-3FFD-4CF7-B131-0FCBAE5F75FCQ43143208-509EBB3E-7A64-4DA8-841B-FD95DE9462E8Q43165529-364A38E4-421A-4037-83B4-90146F5EFB01Q43297939-4498D9D0-8F80-4BDE-8237-A5604D61B36FQ43498064-3CD44EC6-1A48-47F3-B75D-13B1083D3F52Q43704129-6DABF88D-1308-4EA7-B42C-999C757C899EQ45145788-A6A9E0BE-3738-4AA7-B764-7E67568FA87B
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականին հրատարակուած գիտական յօդուած
@hyw
2007 թվականին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Measuring antiplatelet drug effects in the laboratory
@ast
Measuring antiplatelet drug effects in the laboratory
@en
Measuring antiplatelet drug effects in the laboratory
@nl
type
label
Measuring antiplatelet drug effects in the laboratory
@ast
Measuring antiplatelet drug effects in the laboratory
@en
Measuring antiplatelet drug effects in the laboratory
@nl
prefLabel
Measuring antiplatelet drug effects in the laboratory
@ast
Measuring antiplatelet drug effects in the laboratory
@en
Measuring antiplatelet drug effects in the laboratory
@nl
P2093
P3181
P1433
P1476
Measuring antiplatelet drug effects in the laboratory
@en
P2093
A L Frelinger
Alan D Michelson
Mark I Furman
P304
P3181
P356
10.1016/J.THROMRES.2006.11.012
P407
P577
2007-01-17T00:00:00Z